Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial) (PPAR)

NCT00745225 Phase 4 COMPLETED

To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients

Details

Lead sponsor	The University of Hong Kong
Phase	Phase 4
Status	COMPLETED
Enrolment	160
Start date	2006-02
Completion	2014-12

Conditions

• End-stage Renal Disease

Interventions

• Pioglitazone
• placebo comparator

Primary outcomes

• Change in carotid intima-media thickness — over 48 weeks
  Change in carotid intima-media thickness
• change in flow mediated dilatation (marker of endothelial function) — over 48 weeks
  change in flow mediated dilatation (marker of endothelial function)

Countries

Hong Kong